Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/25/2018 |
| Start Date: | August 9, 2006 |
| End Date: | October 14, 2014 |
A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin's Lymphoma
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as
rituximab, can block cancer growth in different ways. Some block the ability of cancer cells
to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them. Giving bortezomib together with rituximab may kill more cancer cells.
This phase II trial is studying how well giving bortezomib together with rituximab works as
first-line therapy in treating patients with low-grade B-cell non-Hodgkin's lymphoma.
cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as
rituximab, can block cancer growth in different ways. Some block the ability of cancer cells
to grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them. Giving bortezomib together with rituximab may kill more cancer cells.
This phase II trial is studying how well giving bortezomib together with rituximab works as
first-line therapy in treating patients with low-grade B-cell non-Hodgkin's lymphoma.
This is a multicenter, prospective study.
- Induction therapy: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and
22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1
of all subsequent courses. Treatment repeats every 35 days for 3 courses. Patients
achieving a complete response, partial response, or stable disease proceed to
maintenance therapy.
- Maintenance therapy: Beginning 6-8 weeks after induction therapy, patients receive
bortezomib IV over 3-5 seconds and rituximab IV on day 1. Treatment repeats every 60
days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Blood and tissue samples are collected at baseline and periodically during study treatment.
After completion of study therapy, patients are followed every 3 months for 2 years.
- Induction therapy: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and
22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1
of all subsequent courses. Treatment repeats every 35 days for 3 courses. Patients
achieving a complete response, partial response, or stable disease proceed to
maintenance therapy.
- Maintenance therapy: Beginning 6-8 weeks after induction therapy, patients receive
bortezomib IV over 3-5 seconds and rituximab IV on day 1. Treatment repeats every 60
days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Blood and tissue samples are collected at baseline and periodically during study treatment.
After completion of study therapy, patients are followed every 3 months for 2 years.
Inclusion Criteria:
- Histologically confirmed low-grade B-lymphocyte non-Hodgkins lymphoma
- Life expectancy > 12 months
Exclusion Criteria:
- No known history of HIV infection
- No other active infection
- No peripheral neuropathy ≥ grade 2 within the past 14 days
- No uncontrolled hypertension
- None of the following cardiac conditions:
- Myocardial infarction within the past 6 months
- No heart failure
- Uncontrolled angina
- Severe uncontrolled ventricular arrhythmias
- Electrocardiographic evidence of acute ischemia
- Active conduction system abnormalities
- No serious medical or psychiatric illness that would preclude study compliance
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior therapy for non-Hodgkins lymphoma
- No prior bortezomib or rituximab
- At least 3 weeks since prior chemotherapy, radiation therapy, immunotherapy, systemic
anticancer biologic therapy, or anticancer hormonal therapy
- At least 2 weeks since prior investigational drugs
- No other concurrent systemic cytotoxic chemotherapy or investigational agents + No
leukemia
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials